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THE USE OF THE HORMONES IN DERMATOLOGY'
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T he endocrine glands exert far reaching effects that we are only now beginning
to understand. Aside from the direct specific effects of the various endo-
crinopathies on the skin, there may be effects mediated through the autonomic
nervous system. Endocrine dysfunction may affect the emotional state and
aggravate or initiate psycho-somatic disorders. Allergic disturbances, in eluding
those of the skin, comprise an important group of ailments. That specific
sensitivities arc not the complete answer to the etiology of allergic disorders,
and that the approach by many of them is not the invariable answer to their
treatment has long been known. Why a given allergen can at one time provoke
a clinical manifestation of allergy and at other times not, is determined by
factors which modify the allergic status. Endocrine dysfunctions are among
the important factors modifying this status.
It is obvious that some knowledge of endocrinology is a necessity to the
dermatologist wishing to arm himself \vith the maximum in effective therapeutic
weapons. A summary of the clinical and experimental uses of hormones in
dermatology is herein presented under three logical headings:
A. 5KIN DISORDERS DUE TO THR DEFIC1RNCY OR ABSENCR OF A SPRCIFIC ENDOCRINE
PRODUCT RRSPONDING TO SUBSTITUTIVE THERAPY
rihe following phenomena should be matters of common knowledge: 1) The
brownish pigmentation of adreno-cortieal deficiency (Addison's disease) being
arrested and even reversed by adrenal cortex extracts and the synthetic desoxy-
corticosterone acetate. 2) The myxedema of hypothyroidism being fully cor-
rected by dessicated thyroid or thyroxin. 3) The urticaria and dermographia
of dystrophia adiposogenitalis, Froelieh's syndrome of anterior pituitary de-
ficiency, responding to either pituitary or chorionic gonadotropin, but better
to the combination. 4) The gradual disappearance of the lesions of xanthoma
diabeticorum with insulin, a high-carbohydrate, low animal-fat diet, and thyroid,
if the basal metabolism is low. 5) The itching of pruritus vulvae of the cli-
macteric and the atrophic changes of senile vaginitis being abolished by estrogens.
The component of kraurosis vulvae due to estrogen deficiency also responds,
leaving only the degenerative inflammatory portion to combat. 6) The skin
manifestations of ordinary diabetes mellitus responding to insulin, carbohydrate
restriction, or both.
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Less well known but certainly not uncommon is so-called "skin diabetes",
which Urbach has described under the name "independent cutaneous glyco-
histechia" (1). Urbach, for whom the disorder should really be named because
of his brilliant investigational work, has used microchemical methods to show
that the skin sugar may be significantly raised, even when the urine is negative
and the fasting blood sugar is normal. According to Urbach's findings, the
average skin sugar could be shown to be 58 mg. per 100 grams and abnormal
values to be above 68 mg. per 100 grams. In Urbach's results, the average
ratio between skin sugar and blood sugar was 61 per cent. When the ratio is
70 per cent or more one is justified in speaking of "independent cutaneous
glycohistechia". According to Urbach, the skin lesions, most apt to occur in
elderly, obese individuals with a purplish-red complexion, clear promptly on
carbohydrate restriction, insulin administration, or both. Usually restriction
is sufficient. If [Jrbach's results are confirmed, many of the therapy-resistant
cases that dermatologists have cleared empirically by carbohydrate restriction
have probably been Urbach's disease.
The term chloasma is used to cover many types of pigmentary disturbances.
Two of these, the common chloasma gravidarum and the less common meno-
pausal chloasma, are due to estrogen excess and estrogen deficiency respectively.
The hyperpigmentation of pregnancy is caused by the direct stimulation of the
melanoblast cells by the high estrogen concentrations characteristic of pregnancy
and is always limited to areas naturally containing pigment, such as the nipples,
areola, linen alba and face. Hyperpigmentation of the menopause may affect
other areas, arid signs of skin senescence are present. The author noted clearing
of the lesions in 12 of 17 menopausal patients under estrogen therapy and has
never seen such pigmentation develop in the menopausal group as a result of
such therapy. The fact that young women with amenorrhoea due to estrogen
deficiency and lack of pigmentation will develop normal pigment as a result of
estrogen therapy (2) shows that there must be a difference in pigmenting proces-
ses in the two age groups.
B. SKiN DISORDERS NOT DUE TO A SPECIFIC HORMONE DEFICIENCY, BUT IN WHICH
A HORMONE HAS A SPECIFIC USEFUL EFFECT
Urticaria and angioneurotic edema are helped temporarily by vasoconstrictors,
the two most effective beillg epinephrine from the adrenal medulla and the pitres-
sin from the posterior portion of the pituitary gland. The action of epinephrine
is the more rapid but the central stimulation is a disadvantage. Although not
as intense initially, the action of pitressin is more prolonged. Experienced
clinicians usually find it advantageous to combine them. In serum sickness
the virtues of this combination are even more evident.
The discovery that insulin exerts a beneficial effect in urticaria was made
during investigations of serum potassium levels in allergic states (3). The
serum potassium in normal individuals averages 19.5 mg. per 100 cc., ranging
from 17.9 to 20.6. In acute and chronic urticaria the range is from 22 to 25.3 mg.
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per 100 cc., with an average of 23.4. Apparently the serum potassium increases
at the expense of the tissue cell potassium; the loss of potassium by the latter
may be a significant factor. The administration of insulin, epinephrine par-
enterally, or dextrose intravenously bring about simultaneous relief of symptoms
and a drop in the serum potassium level. Insulin plus dextrose administration
is more effective than either alone. Quite significantly, none of the cases in
whom this beneficial effect of insulin has been observed has been a diabetic.
Papular urticaria not only differs from the ordinary variety in appearance,
out also in its response to maintained high serum calcium levels. Parathyroid
hormone here serves a useful purpose in cutting down the frequency of injections
of calcium salts or doing away with such injections entirely. Parathyroid
hormone is not meant to be used indefinitely, however, as people with this dis-
order almost invariably have serum calciums within the normal range.
It is difficult to see why a majority of cases of herpes zoster should be sympto-
matically relieved by injections of pitressin. If the cutaneous lesions of herpes
zoster are due to the liberation of H-substance from the epidermal cells by
antidromic impulses from the inflamed posterior root ganglion, epinephrine
should also be effective. The author tried the effect of each, given separately
in 18 cases of herpes zoster. Fourteen of these cases claimed relief of symptoms
from the pitressin and only 2, both more relieved by pitressin, from epinephrine.
Next came a group of unrelated disorders more or less aided by dessicated
thyroid because of certain of its non-specific physiologic effects: the minority
of xanthoma tuberosum cases respond because of the more rapid utilization of
fat incident to the raised metabolic rate. A majority of xeroderma cases and
a minority of the more severe, and usually congenital iehthyosis simplex cases
make some improvement because of the increased sweat and sebaceous gland
activity and more rapid epidermal regeneration. Seborrheie dermatitis shows
some improvement, but only if the pre-treatment basal metabolism is lower than
average; disordered fat metabolism is probably to blame.
Though most often these skin findings have no relation to a pituitary disease,
demonstrable transient mottling, purpuric spots, dark brown patches on the
legs, hirsutism and symmetrical purplish striae over the axillary folds and
popliteal spaces and trunk form a part of Cushing's syndrome. This syndrome
is due either to primary adreno-cortical overactivity or overactivity secondary
to a basophilic adenoma of the pituitary. For the primary type only the surgical
removal of the diseased adrenal is of avail. When pituitary basophilism is
the cause, estrogen therapy to inhibit the hyperactive basophile cells has been
successfully used (4).
Gonorrheal vulvovaginitis before puberty presents a special problem because
the immature vaginal mucosa is particularly susceptible to bacterial invasion.
Temporary elevation of the epithelial cells to maturity by estrogen therapy, with
a resulting thickening of the membrane, increase in the glycogen content of the
epithelial cells, production of lactic acid and more acid pH (5), permits more
rapid control of the infection and prevents recurrences. Gonococci do not
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thrive in a pH below 6. The route employed may be intramuscular, oral or
vaginal, the last being preferable. Even the most ferveilt advocates of sul-
fonamide and penicillin therapy admit the advisability, if not the necessity,
of a short period of estrogen therapy in this group. Gonorrhea after the meno-
pause may similarly require estrogen for its more rapid or permanent eradicatioii.
Trichomonas vulvovaginitis in the menopausal and post-menopausal periods
offers a comparable problem with the above. Here we are dealing with an
infection on an epithelial surface going through atrophic changes and the net
effect is the same as underdevelopment, namely, lowered resistance to infection
and neutral or alkaline reaction. The protozoan nature of the invader denies
the ailing female the spectacular effects of the sulfonamides and penicillin,
and treatment takes the form of local use of such preparations as silver picrate,
vioform, carbarsone, etc. Whatever therapy is used, it is the universal ex-
perience of the gynecologist or dermatologist that it takes at least two or three
times longer to cure the ailment after the menopause than before it. If adequate
estrogen is administered concommitantly with the usual local therapy, however,
the latter group takes no longer to clear up than the former.
Mention has been made of chloasma after the menopause responding to
estrogen therapy. The more common chloasma of pregnancy, chloasma
gravidarum, presented the opposite problem, that of neutralizing the excessive
estrogen of pregnancy or diminishing its rate of formation. Although the
action of estrogens on the melanoblast cells is a direct one, evidence points to
normal anterior pituitary function as being a necessity (2). The author reasoned
that the cautious administration of androgen might (a) neutralize the estrogen,
(b) diminish anterior pituitary secretory activity, or (c) diminish the anterior
pituitary stimulation of estrogen production by the ovaries, the ehoriome
source remaining uninfluenced. Such experimentation necessarily had to be
exceedingly cautious and only in cases that were advancing so rapidly that they
were being grossly disfigured or becoming psychiatric problems. Of 18 such
cases, 9 were kept as controls and 9 treated with methyl testosterone orally.
Dosage employed was 10 mg. once or twice daily for 2 to 4 weeks, and a total
of 300 mg. was never exceeded. The results were gratifying: in 7 of the 9
treated cases the progress of the skin lesions was promptly arrested, and the rate
of regression of the lesions was much faster than in the control group. No
effect on either the offspring or the course of labor was noted.
C. SKIN DISORDERS iN WHICH ENDOCRINE MALFUNCTION MAY BE A
PRECIPITATING OR AGGRAVATING FACTOR
This group includes atopic dermatitis, which is usually of allergic origin,
urticaria, which often is, and acne vulgaris or juvenilis, which only infrequently
is. A minority of cases of each gives the impression of thyroid or gonadal
malfunction. The following chart summarizing the author's experiences with
thyroid medication of atopic dermatitis, urticaria and acne is presented:
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BAS1L MET%BOLISI RANGE CASES TREATEDWITH THYROID
CASES BENEFITED
BY THYROID
Atopic dermatitis: Ages
ranging from 9 to 47—
67 eases
Above +20%
+20 to +10
+10 to —10
—lOto—20
None
3
48
7
None
None
25
7
—
—
3
5
—2Oto—25 6 6 5
Below —25 3 3
41
—
None
32
9
3
16
—..
——
3
4
Totals 67
tJrticaria: Ages ranging
from 10 to 61—61 Cases
Above +20% None
+20 to +10 7
+10 to —10 41
—10 tC) —20 9
Below —20 4
Totals 61
Acne vulgaris: ages rang- Above +20% 2
ing from 13 to 32—62 +20 to +10 7
cases +10 to —10 41
—10 to —20 9
Below —20 3
Totals 62
4 2
45 0
None
None —
30 10
9 7
3 2
42 10
The data permit a few conclusions to be drawn:
1. In atopic dermatitis and urticarias abnormally high basal metabolic rates
were not encountered.
2. In atopie dermatitis and urticarias there were significantly more cases
below the normal range of +10 per cent to —10 per cent than above. This
was most notable with atopic dermatitis.
3. The acne group was fairly symmetrically divided in the percentage brackets.
4. In all three categories the per cent benefitted from thyroid administration
was proportionate to the need, as indicated by the basal metabolic rates.
5. TJrticaria was the least benefitted, 9 out of 45 (20 per cent), and acne
the most, 19 out of 42 (45 per cent). In atopic dermatitis, benefit was inter-
mediate, with 16 out of 41 (39 per cent).
The female patient from puberty to menopause presents a constantly changing
sex hormone picture. Oniy before the upheaval of puberty and after the
menopausal decline can she be considered endocrinologically static. Even the
hormonal fluctuations of the menstrual cycles during the period of sexual maturity
are altered by incidental pregnancies. It therefore behooves the therapist to
first correlate the onset, exacerbation or disappearance of the skin lesions with
the events of the menstrual cycle, pregnancy, puberty, or the climacteric.
To this end a short resumé of pituitary and ovarian function is in order:
In childhood the blood concentration of estrogen (female sex hormone) is
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low and relatively constant. Under the influence of the anterior pituitary
follicle stimulating hormone (FSII) (Thylakentrin) at puberty the ovary produces
estrogens which in turn promote the secondary sex characteristics. Menstrual
cycles then put in their appearance. At the time of menstruation estrogen is
at its lowest level. Thylakentrin then stimulates a primordial follicle to grow
and the ovary in general, but the follicle in particular to produce estrogen.
Blood estrogen levels increase until ovulation, when there is a sudden drop
(after which there may be slight intermenstrual bleeding), followed by a second
and higher peak at about the twenty-second day of the cycle. There is an
accompanying peak of progesterone, which has been produced from the corpus
luteum since ovulation in increasing amounts, along with estrogen under the
stimulation of the anterior pituitary luteinizing hormone (LII) (Tvletakentrin).
The concentration of both then drops, particularly rapidly at about the twenty-
sixth day, to their lowest levels of the cycle, during menstruation and the few
days following. There is an interesting reciprocal relationship, as the rising
estrogen concentration inhibits the production or release of the anterior pituitary
sex hormones (6, 9). Cyclic uterine bleeding, whether ovulatory or anovulatory,
is due essentially to a preceding drop in the blood estrogen level, allowing en-
dometrial regression and degeneration (7). At the climacteric the ovary is
no longer effectively responsive to pituitary stimulation, estrogen is not produced
in sufficient quantity to inhibit the pituitary, and the familiar menopausal
symptoms result, presumably because of the presence of excess anterior pituitary
sex hormones, particularly Thylakentrin (8). The administration of estrogen,
preferably, but even androgen, can relieve these symptoms by inhibiting the
anterior pituitary.
Rare cases of urticaria related to puberty are transient, and the result of
the emotional state, hence better controlled by psychotherapy than hormones.
Menopausal urtiearias, resulting from dysfunction of the vasomotor mechanisms
are controlled by the administration of estrogen in the majority of eases (85
per cent in the author's series). With the restoration of the normal pituitary-
ovarian hormone relationship, the urtiearial difficulties end with the others.
The therapist then allows a gradual transition to the post-menopausal state
instead of a sudden one to prevent recurrences.
Premenstrual urtiearia and menstrual urticaria are fundamentally different
in etiology and it is important to distinguish between them, as their treatment
differs radically.
Menstrual urtiearia does not make its appearance until the day before men-
struation at the earliest, but usually on the first day. There is ordinarily
more or less nervousness, irritability, dysmenorrhea, and abnormality of flow;
little or no fever is the rule. Simple sedatives may work wonders but the physio-
logical preventative is an injection of estrogen, preferably one of the estradiol or
"natural" series so times as to give an optimum concentration when needed.
Dose and timing vary with the patient. It usually requires a dose of 1 to 2
milligrams of alpha-estradiol dipropionate or benzoate given intramuscularly2 to 4 days before the onset of the period. Of19 such eases, the author has had
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unsatisfactory results in only 2; the rest enjoyed complete prevention of the urti-
caria or marked minimization. The dysmenorrhea, when present, was not
consistently affected.
Premenstrual urticaria is associated with premenstrual tension, classically
including nausea, headache, fever, nervous tension and lower abdominal and
back pains. The symptoms are present for from 5 to 7 days before the onset
of the period and end as menstruation begins. These patients suffer from too
much estrogen (10, 11); the post-ovulatory or premenstrual blood estrogen
concentration rises to a height which gives toxic manifestations, or, as Zondek's
report suggests, they are allergic to their own endocrine products (12). When
this latter group is tested intradermally with estradiol or estrone in oil (0.1 nig.
in 0.1 cc. oil) with a simultaneous oil control a positive skin test is obtained.
It is either papular or erythematous, usually coming on in 3 to 5 hours and
persisting at least a day. A passive transfer of their premenstrual serum to
normal women will give positive tests with estradiol, but the normal recipient's
untreated site will not react to estradiol. In the menstrual urticaria group
neither the direct nor the passive transfer test can be elicited. Two types of
treatment are available in the premenstrual group. The first that the author
has used successfully is the administration of 10 milligrams of methyl testosterone
orally twice daily for 10 days before the expected period. This depresses the
anterior pituitary function, which, in turn, results in less production of estrogen
by the ovary; a direct antagonism of androgen and estrogen is also a possibility
(13). Of 12 cases treated in this manner, 11 responded satisfactorily. The
second treatment is subcutaneous or intramuscular desensitization to alpha-
estradiol, starting with the amount just failing to give a positive skin test.
The succeeding doses are given every 2 or 3 days; 7 out of 10 cases treated in
this way gave an excellent response. It is of interest to note that urticarial
attacks occurring in the premenstrual period can be duplicated in the inter-
menstruum by injecting serum taken during the pre-menstrual period (14).
TJrtiearia in the male offers no comparable problems except in the elimacterie
and sex hormone treatment is rarely justified or indicated. The male elimacterie
is occasionally accompanied by urtiearia and generalized itching without visible
lesions is not uncommon. The response to substitutive therapy with androgens
is good. Acne and eczema in the male, before we discuss these disorders in
the female, are best left alone from the sex hormone standpoint. In our present
state of knowledge we can do no good to the male's acne or atopic dermatitis,
and we could conceivably harm his pituitary-gonadal equipment.
Acne and atopie dermatitis in the female offer comparable, but not as clear-
cut features as urtiearia in the female. One gets the impression that there are
menstrual and premenstrual types, but the persistence of the lesions makes
distinctions difficult. The menstrual type has given only fair response to
estrogen treatment; indeed, the advisability of such therapy in the young female,
for the most part inconclusive in results, is debatable. In 2 of 6 "premenstrual
aenes" oral methyl testosterone therapy gave fair results; the other results
were equivocal. Desensitization with their own blood serum taken during the
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premenstrual phase (15) gave good results in 3 such acne cases and failures in 4.
Four out of 5 "premenstrual acnes" giving positive estrogen skin tests benefitted
by estradiol desensitization therapy. In general, the author cannot help but
feel that sex hormone therapy in this group is rarely indicated.
The treatment of asymptomatic skin senescence by sex hormones belongs in
the business of cosmetology rather than the practice of medicine. The process
of aging has more than its hormonal aspects. While it is true that the topical
application or internal administration of estrogen in the female and androgen
in the male can make perceptible changes in the appearance and texture of the
skin, the effects are temporary and never fully corrective. It is questionable
whether the results attained are worth the risks involved in the necessarily pro-
longed treatment. In experimental animals prolonged high estrogen therapy
results in pituitary changes, the basophile cells becoming completely degranulated
the acidophiles almost totally degranulated, and large chromophobic adenomata
forming. Uncontrolled androgen therapy can lead to prostatic hypertrophy
and neoplasm in susceptible men. Topical application of estrogens along with
unpredictable absorption has the potential danger of carcinogenesis. Although
the small dosage usually used in topical applications has never been shown to
produce tumors and must therefore at present be considered "safe", protracted
estrogen stimulation by any route, plays a part in the growth of uterine fibroids
(16, 17), endometriomata (18), and cervical neoplasms (19). The incidence
of carcinoma of the breast also is believed to be increased by prolonged estrogen
stimulation (20, 21).
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